Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tyler C Detomasi

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Protein Science : a Publication of the Protein Society|June 24, 2023
Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitorsElissa A Fink, Conner Bardine, Stefan Gahbauer, et al.
Journal of Medicinal Chemistry|January 6, 2026
Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection ModelsLuca Lizzadro, Jiapeng Li, Taha Y Taha, et al.
Science Advances|April 23, 2025
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M<sup>Pro</sup> inhibitors with potent in vivo efficacyTyler C Detomasi, Gilles Degotte, Sijie Huang, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Protein Science : a Publication of the Protein Society|June 24, 2023
Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitorsElissa A Fink, Conner Bardine, Stefan Gahbauer, et al.
Journal of Medicinal Chemistry|January 6, 2026
Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection ModelsLuca Lizzadro, Jiapeng Li, Taha Y Taha, et al.
Science Advances|April 23, 2025
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M<sup>Pro</sup> inhibitors with potent in vivo efficacyTyler C Detomasi, Gilles Degotte, Sijie Huang, et al.
Pageof 2